Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo

Abstract Glucagon-like peptide 1 receptor (GLP-1R) agonist is an emerging anti-diabetic medication whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial. This study aimed to elucidate the roles of GLP-1R and its agonists on intrahepatic CCA (iCCA) progression. Expre...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ronnakrit Trakoonsenathong, Waritta Kunprom, Chaiwat Aphivatanasiri, Padcharee Yueangchantuek, Paslada Pimkeeree, Supannika Sorin, Kullanat Khawkhiaw, Ching-Feng Chiu, Seiji Okada, Sopit Wongkham, Charupong Saengboonmee
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-06-01
Colecção:	Scientific Reports
Assuntos:	Cholangiocarcinoma Diabetes mellitus Glucagon-like peptide 1 receptor Liraglutide
Acesso em linha:	https://doi.org/10.1038/s41598-024-64774-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!